Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Common Equity (2023 - 2025)

Monte Rosa Therapeutics' Common Equity history spans 3 years, with the latest figure at $233.1 million for Q4 2025.

  • For Q4 2025, Common Equity rose 4.54% year-over-year to $233.1 million; the TTM value through Dec 2025 reached $233.1 million, up 4.54%, while the annual FY2025 figure was $233.1 million, 4.54% up from the prior year.
  • Common Equity reached $233.1 million in Q4 2025 per GLUE's latest filing, down from $245.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $275.2 million in Q1 2025 to a low of $152.5 million in Q1 2024.
  • Average Common Equity over 3 years is $220.7 million, with a median of $223.8 million recorded in 2024.
  • Peak YoY movement for Common Equity: tumbled 37.42% in 2024, then soared 80.41% in 2025.
  • A 3-year view of Common Equity shows it stood at $179.2 million in 2023, then increased by 24.37% to $222.9 million in 2024, then rose by 4.54% to $233.1 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Common Equity are $233.1 million (Q4 2025), $245.8 million (Q3 2025), and $268.1 million (Q2 2025).